GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » C4 Therapeutics Inc (NAS:CCCC) » Definitions » PEG Ratio

CCCC (C4 Therapeutics) PEG Ratio : 0.00 (As of Apr. 15, 2025)


View and export this data going back to 2020. Start your Free Trial

What is C4 Therapeutics PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, C4 Therapeutics's PE Ratio without NRI is 0.00. C4 Therapeutics's 5-Year EBITDA growth rate is 36.10%. Therefore, C4 Therapeutics's PEG Ratio for today is 0.00.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for C4 Therapeutics's PEG Ratio or its related term are showing as below:



CCCC's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.38
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


C4 Therapeutics PEG Ratio Historical Data

The historical data trend for C4 Therapeutics's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

C4 Therapeutics PEG Ratio Chart

C4 Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PEG Ratio
Get a 7-Day Free Trial - - - - -

C4 Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of C4 Therapeutics's PEG Ratio

For the Biotechnology subindustry, C4 Therapeutics's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


C4 Therapeutics's PEG Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, C4 Therapeutics's PEG Ratio distribution charts can be found below:

* The bar in red indicates where C4 Therapeutics's PEG Ratio falls into.


;
;

C4 Therapeutics PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

C4 Therapeutics's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/36.10
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


C4 Therapeutics  (NAS:CCCC) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


C4 Therapeutics PEG Ratio Related Terms

Thank you for viewing the detailed overview of C4 Therapeutics's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


C4 Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
490 Arsenal Way, Suite 120, Watertown, MA, USA, 02472
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
Executives
Scott N Boyle officer: Chief Business Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Mark Mossler officer: Chief Accounting Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 120, WATERTOWN MA 02472
Kendra Adams officer: Chief Financial Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 120, WATERTOWN MA 02472
Leonard Reyno officer: Chief Medical Officer 607 NORTH LAS PALMAS AVENUE, LOS ANGELES CA 90004
Utpal Koppikar director C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO CA 94080
Donna Roy Grogan director 1133 OLD QUEEN ANNE ROAD, CHATHAM MA 02633
Laura Bessen director 4747 EXECUTIVE DRIVE, SUITE 1150, SAN DIEGO CA 92121
Andrew Hirsch director, officer: See Remarks C/O BIND THERAPEUTICS, INC., 325 VASSAR ST, CAMBRIDGE MA 02139
Kelly Schick officer: Chief People Officer C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Malcolm Salter director C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Adam Crystal officer: Chief Medical Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Elena Prokupets director C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Jolie Siegel officer: Chief Legal Officer C/O NEON THERAPEUTICS, INC., 40 ERIE ST., SUITE 110, CAMBRIDGE MA 02139
Stewart Fisher officer: Chief Scientific Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Lauren White officer: Chief Financial Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472